ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Lilly to seek FDA approval for potential Alzheimer's drug

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Jun 24, 2021 4:49pm

147 Views

Post# 33445770

RE:Lilly to seek FDA approval for potential Alzheimer's drug

This is exactly what we need to start happening...there is so.much controversy right now on the Biogen approval that the world will completely go bonkers if a company comes out with a drug that deals with the problems and shortcomings Biogen had .. basically these pissed off people will be so blinded with rage that anyone coming out with a better product is going to be very popular...great position for.pmn to.be in...

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources